As the mental health benefits of the magic mushroom-derived drug psilocybin become more mainstream, researchers and developers are looking for ways to make new drugs more accessible for clinical therapy. Born out of the desire to create psychedelic compounds more scalable than psilocybin, biotech startup EntheogeniX wants to make new, short-acting drugs that are “pharmacologically … Continue reading Biotech startup wants to make new short-acting psychedelic drugs more scalable & accessible